Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3799-3802

  Lenartz, D ^a   Stoffel, B ^b   Menzel, J ^a   Beuth, J ^b  

^a KLINIKUM CHEMNITZ   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Glioma patients; Lectin 1; Mistletoe; Protection; Quality of life

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GALACTOSIDE; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2 RECEPTOR; PLANT LECTIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; NEUROSURGERY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VISCUM ALBUM;

BRAIN NEOPLASMS; FEMALE; GALECTIN 1; GLIOBLASTOMA; HEMAGGLUTININS; HUMANS; IMMUNITY, CELLULAR; LECTINS; MALE; MIDDLE AGED; MISTLETOE; PLANT LECTINS; PLANTS, MEDICINAL; PROSPECTIVE STUDIES;

EID: 0030518747     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Beuth J, Stoffel B, Ko HL, Jeljuszewicz J, Pulverer G: Mistellektin-1: neue therapeutische Perspektiven in der Onkologie. Onkologie 18: 36-40, 1995.
2. Beuth J, Stoffel B, Samtleben R, Staak O, Ko HL, Pulverer G, Wagner H: Modulating ability of mistletoe lectins 1 and 2 on the lymphatic system in BALB/c-mice. Phytomedicine 2: 269-273, 1946.
3. Heiny BM, Beuth J: Mistletoe extract standardized for the galactose-specific lectin (ML-1) induces β-endorphin release and immunopotentation in breast cancer patients. Anticancer Res 14: 1334-1342, 1994.
4. Gabius S, Gabius H-J: Mistelpraeparate als Immunstimulatoren in der Onkologie. Nieders Aerzteblatt 64: 16-24, 1991.
5. Beuth J, Gabius H-J, Steuer MK, Geisel J, Steuer M, Ko HL, Pulverer G: Einfluβ der Mistellektintherapie auf den Serumspiegel definierter Serumproteine (Akutphaseproteine) bei Tumorpatienten. Med Klinik 88: 287-290, 1993.
6. Salman M. Epidemiology and factors affecting survival In: Apuzzo MLJ (ed.) Malignant cerebral glioma American Assoc. of Neurological Surgeans, Park Ridge. II, USA, 95-110, 1990
7. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine. and vincristine (PVC) over BCNU for anaplastic gliomas. Int J Radiat Oncol Phys Biol 18: 321, 1990
8. Beuth J, Ko HL, Gabius H-J, Burrichter H, Oette K, Pulverer G: Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specitic lectin from mistletoe in breast cancer patients. Clin Investig 70: 658-661, 1992.
9. Hajto T, Hostanska K, Gabius H-J: Modulatory potency of the β-galactosidc-specific lectin from mistletoe extract (Iscador) on the host defence in vivo in rabbits and patients. Cancer Res 49: 4803-4808, 1989.
10. Beuth J, Ko HL, Gabius H-J, Pulverer G: Determination of lectin-dependent alterations of cellular parameters by immunophenotyping during adjuvant lectin application. In: Gabius H-J, Gabius S (eds.). Lectins and Glycobiology. Springer Verlag 396-401, 1993.
11. Fukazawa H, Ohashi Y, Sekiyama S, Hoshi H, Abe M, Takahashi M, Sato T: Multidisciplinary treatment of head and neck cancer using BCG, OK432, and GE-132 as biological response modifiers. Head Neck 16: 30-38, 1994.
12. Isenberg J, Stoffel B, Wolters U, Beuth J, Stuetzer H, Ko HL, Pichlmaier H: Immunostimulation by propionibacteria: Effects on immune status and antineoplastic treatment. Anticancer Res 15: 2363-2368, 1995.
13. Jurincic-Winkler C, Metz KA, Beuth J, Sippel J, Klippel KF: Effect of keyhole limpet hemocyanin (KLH) and Bacillus Calmette-Guerin (BCO) instillation on carcinoma in situ of the urinary bladder. Anticancer Res 15: 2771-2776, 1995.
14. Beuth J, Ko HL, Tunggal L, Steuer MK, Geisel J, Jeljaszewicz J, Pulverer G: Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo 7: 407-410, 1993.
15. Beuth J, Ko HL, Tunggal L, Buss G, Jeljaszewicz J, Steuer MK, Pulverer G: Immunoprotective activity of the galactoside-specitic mistletoe lectin in cortisone-treated BALB/c-mice. In Vivo 8: 989-992, 1994.
16. Beuth J, Ko HL, Pulverer G: Mistellektin-1: onkologisch relevanter Immunmodulator. Studie bestätigt immunaktive Wirkung. Therapiewoche 27: 1594-1599, 1995.
17. Steuer MK, Bonkowsky V, Strutz J, Beuth J, Kau RJ, Ambrosch P, Neiß A, Kühn A, Arnold W, Pulverer G, Ko HL: Immundefizienz bei Patienten mit Kopt-Hals-Plattenepithelkarzinomen: Fine rationale Grundlage für den Einsatz des Immunmodulators ML-I. Otorbinolaryngol Nova 4: 152-159, 1994.